PURPOSE: Hyperinsulinemia is hypothesized to influence prostate cancer risk. Thus, we evaluated the association of circulating C-peptide, which is a marker of insulin secretion, and leptin, which is secreted in response to insulin and influences insulin sensitivity, with prostate cancer risk. METHODS: We identified prostate cancer cases (n = 1,314) diagnosed a mean of 5.4 years after blood draw and matched controls (n = 1,314) in the Health Professionals Follow-up Study. Plasma C-peptide and leptin concentrations were measured by ELISA. Odds ratios (ORs) and 95 % confidence intervals (CI) were estimated taking into account the matching factors age and history of a PSA test before blood draw and further adjusting for body mass index, diabetes, and other factors. RESULTS: Neither C-peptide (quartile [Q]4 vs. Q1: OR 1.05, 95 % CI 0.82-1.34, p-trend = 0.95) nor leptin (Q4 vs. Q1: OR 0.85, 95 % CI 0.65-1.12, p-trend = 0.14) was associated with prostate cancer risk. Further, neither was associated with risk of advanced or lethal disease (n = 156 cases; C-peptide: Q4 vs. Q1, OR 1.18, 95 % CI 0.69-2.03, p-trend = 0.78; leptin: Q4 vs. Q1, OR 0.74, 95 % CI 0.41-1.36, p-trend = 0.34). CONCLUSIONS: In this large prospective study, circulating C-peptide and leptin concentrations were not clearly associated with risk of prostate cancer overall or aggressive disease. Well into the PSA era, our findings do not appear to be supportive of the hypothesis that hyperinsulinemia influences risk of total or aggressive prostate cancer.
PURPOSE:Hyperinsulinemia is hypothesized to influence prostate cancer risk. Thus, we evaluated the association of circulating C-peptide, which is a marker of insulin secretion, and leptin, which is secreted in response to insulin and influences insulin sensitivity, with prostate cancer risk. METHODS: We identified prostate cancer cases (n = 1,314) diagnosed a mean of 5.4 years after blood draw and matched controls (n = 1,314) in the Health Professionals Follow-up Study. Plasma C-peptide and leptin concentrations were measured by ELISA. Odds ratios (ORs) and 95 % confidence intervals (CI) were estimated taking into account the matching factors age and history of a PSA test before blood draw and further adjusting for body mass index, diabetes, and other factors. RESULTS: Neither C-peptide (quartile [Q]4 vs. Q1: OR 1.05, 95 % CI 0.82-1.34, p-trend = 0.95) nor leptin (Q4 vs. Q1: OR 0.85, 95 % CI 0.65-1.12, p-trend = 0.14) was associated with prostate cancer risk. Further, neither was associated with risk of advanced or lethal disease (n = 156 cases; C-peptide: Q4 vs. Q1, OR 1.18, 95 % CI 0.69-2.03, p-trend = 0.78; leptin: Q4 vs. Q1, OR 0.74, 95 % CI 0.41-1.36, p-trend = 0.34). CONCLUSIONS: In this large prospective study, circulating C-peptide and leptin concentrations were not clearly associated with risk of prostate cancer overall or aggressive disease. Well into the PSA era, our findings do not appear to be supportive of the hypothesis that hyperinsulinemia influences risk of total or aggressive prostate cancer.
Authors: Pär Stattin; Rudolf Kaaks; Robert Johansson; Randi Gislefoss; Stefan Söderberg; Henrik Alfthan; Ulf-Håkan Stenman; Egil Jellum; Tommy Olsson Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-05 Impact factor: 4.254
Authors: Anya Burton; Richard M Martin; Jeff Holly; J Athene Lane; Jenny L Donovan; Freddie C Hamdy; David E Neal; Kate Tilling Journal: Cancer Causes Control Date: 2012-12-08 Impact factor: 2.506
Authors: J Slade Hubbard; Sabine Rohrmann; Patricia K Landis; E Jeffrey Metter; Denis C Muller; Reubin Andres; H Ballentine Carter; Elizabeth A Platz Journal: Urology Date: 2004-02 Impact factor: 2.649
Authors: R Kaaks; A Lukanova; S Rinaldi; C Biessy; S Söderberg; T Olsson; U-H Stenman; E Riboli; G Hallmans; P Stattin Journal: Eur J Cancer Prev Date: 2003-08 Impact factor: 2.497
Authors: P Stattin; S Söderberg; G Hallmans; A Bylund; R Kaaks; U H Stenman; A Bergh; T Olsson Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: Yin Cao; Katharina Nimptsch; Irene M Shui; Elizabeth A Platz; Kana Wu; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci Journal: Int J Cancer Date: 2014-11-10 Impact factor: 7.396
Authors: Katharine N Sourbeer; Lauren E Howard; Gerald L Andriole; Daniel M Moreira; Ramiro Castro-Santamaria; Stephen J Freedland; Adriana C Vidal Journal: BJU Int Date: 2014-10-20 Impact factor: 5.588
Authors: Thomas U Ahearn; Sam Peisch; Andreas Pettersson; Ericka M Ebot; Cindy Ke Zhou; Rebecca E Graff; Jennifer A Sinnott; Ladan Fazli; Gregory L Judson; Tarek A Bismar; Jennifer R Rider; Travis Gerke; June M Chan; Michelangelo Fiorentino; Richard Flavin; Howard D Sesso; Stephen Finn; Edward L Giovannucci; Martin Gleave; Massimo Loda; Zhe Li; Michael Pollak; Lorelei A Mucci Journal: Carcinogenesis Date: 2018-12-31 Impact factor: 4.944
Authors: Benjamin C Fu; Fred K Tabung; Claire H Pernar; Weike Wang; Amparo G Gonzalez-Feliciano; Ilkania M Chowdhury-Paulino; Steven K Clinton; Edmund Folefac; Mingyang Song; Adam S Kibel; Edward L Giovannucci; Lorelei A Mucci Journal: Eur Urol Date: 2021-01-06 Impact factor: 20.096
Authors: Arjun Gupta; Yehuda Herman; Colby Ayers; Muhammad S Beg; Susan G Lakoski; Shuaib M Abdullah; David H Johnson; Ian J Neeland Journal: PLoS One Date: 2016-09-16 Impact factor: 3.240